Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018 30/07/2018 Medications TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) — Read more